Compare Ishares Msci Thailand Etf (THD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Thailand Etf vs TransMedics Group Inc — how do they compare? Ishares Msci Thailand Etf trades at $71.72 (market cap $426.83M), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 6.4× Ishares Msci Thailand Etf's market cap, and Ishares Msci Thailand Etf is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Thailand Etf for 65 Days and TransMedics Group Inc for 24 Days on average.
| THD | TMDX | |
|---|---|---|
Market Cap | $426.83M | $2.74B |
Volume | 82,409 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $75.06 | $150.42 |
52-Week Low | $57.86 | $61.99 |
Typical Hold Time | 65 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
THD trades at $71.80, down 0.15% with a bearish technical outlook as moving averages signal selling pressure. Short interest surged 90.6% in September 2026, indicating growing skepticism. The ETF has delivered strong 38% returns over the past year, outperforming ASEAN peers, but faces headwinds from potential profit-taking in AI-exposed holdings like Delta Electronics.
The outlook is cautious given elevated short interest and technical weakness. While THD benefits from Thailand's AI hardware exposure, concentration risk and regional capital outflows pose challenges. Investors should weigh strong historical performance against near-term sentiment pressures.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
